WO2004091535A2 - Methods of administering estrogens and progestins - Google Patents
Methods of administering estrogens and progestins Download PDFInfo
- Publication number
- WO2004091535A2 WO2004091535A2 PCT/US2004/011662 US2004011662W WO2004091535A2 WO 2004091535 A2 WO2004091535 A2 WO 2004091535A2 US 2004011662 W US2004011662 W US 2004011662W WO 2004091535 A2 WO2004091535 A2 WO 2004091535A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conjugated
- dose
- acetate
- administering
- therapeutic amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Definitions
- the present invention generally relates to a method of treating hormonal deficiencies in women, particularly menopausal and post-menopausal women.
- Menopause typically occurs in women during middle age and is often described as an ovarian shutdown. Menopause is usually associated with a profound decrease in circulating levels of estrogens.
- Menopause is usually associated with a profound decrease in circulating levels of estrogens.
- disorders and conditions include hot flashes, dryness and atrophy of the vagina, parathesia, dyspareunia, osteoporosis, and an increase in cardiovascular disease.
- estrogens are administered to women in a so-called "estrogen replacement therapy”. Estrogen replacement therapy continues to be the primary treatment of such disorders and conditions associated with menopause. Additionally, estrogens may also be used in postmenopausal women in the treatment of osteoporosis and to delay onset of or prevent cardiovascular disease and Alzheimer's disease.
- endometrial hyperplasia refers to the over stimulation of the lining of the uterus, which is a precursor to endometrial or uterine cancer.
- endometrial hyperplasia is a significant issue with estrogen replacement therapy. For example, it has been observed in U.S. Patent No. RE 36,247 to Plunkett, et al., and U.S. Patent No. 5,043,331 to Hirvonen, that the co-administration of progestin can blunt the effect of estrogens. However, side effects often still occur with this co-administration.
- vasomotor hot flashes are a common symptom in women during menopause.
- Vasomotor hot flashes have also been associated with men who have undergone andro gen-deprivation therapy for prostate cancer.
- megestrol acetate a progestational agent, can decrease the frequency of hot flashes. Loblui et al. "Megestrol Acetate for the Prevention of Hot Flashes", The New England Jovnrnal of Medicine, 331 :347-352 (1994).
- the present invention discloses methods of treating vasomotor symptoms, endometrial hyperplasia, and menopause.
- the present invention also discloses various methods of estrogen therapy and hormonal replacement therapy.
- the methods employed by the present invention include administering a low dose of a progestin with estrogen therapy.
- the present invention includes methods of treating endometrial hyperplasia comprising administering a therapeutic amount of an estrogenic compound to a subject; and administering a therapeutic amount of a progestational agent of less than 20 mg.
- the present invention also discloses methods of treating endometrial hyperplasia comprising administering a therapeutic amount of an estrogenic compound to a subject; and administering a therapeutic amount of a progestational agent of less than 20 mg, wherein said progestational agent is megestrol acetate.
- the present invention recites methods of treating vasomotor symptoms comprising administering a first dose of a therapeutic amount of an estrogenic compound to a subject; administering a second dose of a therapeutic amount of an estrogenic compound at a later time period to the subject, said second dose comprising a lower dosage of said therapeutic amount of an estrogenic compound than said first dose; and administering a therapeutic amount of a progestational agent of less than 20 mg.
- the present invention also recites methods of treating menopause comprising administering a therapeutic amount of an estrogenic compound to a subject; and administering a therapeutic amount of a progestational agent of less than 20 mg.
- the present invention may include methods of treating endometrial hype ⁇ lasia comprising administering a dose of a therapeutic amount of an estrogenic compound to a subject; administering a dose of a therapeutic amount of less than 20 mg of megestrol acetate to a subject; and administering a second dose of a therapeutic amount of megestrol acetate at a later time period to the subject, said second dose comprising a lower dosage of said therapeutic amount of megestrol acetate than said first dose.
- the present invention also discloses methods of treating vasomotor symptoms comprising administering a dose of a therapeutic amount of an estrogenic compound to a subject; administering a dose of a therapeutic amount of less than 20 mg of megestrol acetate to a subject; and administering a second dose of a therapeutic amount of megestrol acetate at a later time period to the subject, said second dose comprising a lower dosage of said therapeutic amount of megestrol acetate than said first dose.
- the invention relates to a method of administering a pharmaceutical composition.
- the pharmaceutical composition comprises a therapeutically effective amount of an estrogenic compound, a therapeutically effective amount of a progestational agent and a pharmaceutically acceptable carrier.
- the composition may also comprise an androgenic compound, wherein the androgenic compound is preferably a non- aromatizing androgen.
- a "therapeutically effective" amount as used herein is an amount of an estrogenic compound that is sufficient to treat hormonal deficiencies in a subject.
- the therapeutically effective amount will vary with the age and physical condition of the patient, the severity of the treatment, the duration of the treatment, the nature of any concurrent treatment, the pharmaceutically acceptable carrier used and like factors within the knowledge and expertise of those skilled in the art.
- Pharmaceutically acceptable carriers are preferably solid dosage forms such as tablets or capsules.
- Liquid preparations for oral administration may be also be used and may be prepared in the form of syrups or suspensions, e.g.,, solutions containing an active ingredient, sugar, and a mixture of ethanol, water, glycerol, and propylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, and saccharin. Thickening agents such as carboxymethylcellulose may also be used. Additionally, transdermal patches and other acceptable carriers, the selection of which are known in the art.
- Estrogen levels are related to the general physiological health of postmenopausal women. Estrogens exert positive central nervous system (CNS) effects on hot flashes, and improve nerve transmission which is believed to delay various types of dementia. They have positive cardiovascular effects by improving lipid levels and promoting vasodilation and relaxation. They also contribute to health of the vagina, provide local vasodilation effects and stimulate mucous production.
- Suitable estrogenic compounds include estrone, 17 ⁇ -estradiol, 17 ⁇ -estradiol, equilin, 17 ⁇ -dihydroequilin, 17 ⁇ -
- the estrogenic compounds may also be present as conjugated estrogens.
- a composition of these compounds may include a mixture that comprises salts of
- estrone conjugated equilin, conjugated ⁇ -dehydroestrone, conjugated 17 ⁇ - estradiol, conjugated 17 ⁇ -dihydroequilin, conjugated 17 ⁇ -dihydroequilin, conjugated 17 ⁇ - estradiol, conjugated equilenin, conjugated 17 ⁇ -dihydroequilenin, and conjugated 17 ⁇ - dihydroequilenin.
- Another composition may include estrone, equilin, 17 ⁇ -dihydroequilin, 17 ⁇ -dihydroequilin and 17 ⁇ -estradiol.
- the conjugates may be various conjugates understood by those skilled in the art, including, but not limited to, glucuronide, sulfate, phosphate and pyrophosphate.
- the most preferred estrogen conjugates are estrogen sulfates.
- the estrogenic compounds may also be present as salts of estrogens conjugates.
- the salts may be various salts understood by those skilled in the art, including, but not limited to, sodium salts, calcium salts, magnesium salts, lithium salts, and piperazine salt. The most preferred salts are sodium salts.
- the estrogenic compounds can be derived from natural and synthetic sources.
- the therapeutically effective amount of estrogenic compound is about 0.05 to about 5 mg, and preferably about 0.25 to about 3 mg based on oral dose equivalents of estradiol. Even more preferable the therapeutically effective amount of the estrogenic compound is about 0.45 to about 2 mg. Even more preferable the therapeutically effective amount of the estrogenic compound is about 0.625 to about 1.5 mg.
- Suitable androgenic compounds include both aromatizing and non- aromatizing compounds.
- Non-aromatizing compounds include as oxandrolone, oxymetholone, stanozolol, stanozolone, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing.
- the therapeutically effective amount of the androgenic compound is about 0.25 to about 10 mg.
- the oral dosage equivalents of oxandrolone is about 0.5 to 4 mg of an androgenic compound per day.
- a progestational agent may be used in combination with the estrogenic compound.
- Examples of progestational agents are set forth in U.S. Patent No. Re. 36,247 to Plunkett et al., the contents of which are incorporated by reference in their entirety.
- Examples include, but are not limited to, laevo-norgestrel, dl- norgestrel, norethindrone (norethisterone), norethindrone (norethisterone) acetate, ethynodiol diacetate, dydrogesterone, medroxyprogesterone acetate, norethynodrel, allylestrenol, lynoestrenol, quingestanol acetate, medrogestone, norgestrienone, dimethisterone, ethisterone, and cyproterone acetate.
- Another progestational agent is megestrol acetate.
- Megestrol acetate has the chemical name Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6- methyl-, a formula of C H 32 O 4 and a molecular weight of 384.51.
- the estrogen formulations of the present invention may be, for example, in the form of tablets; effervescent tablets; pills; powders; elixirs; suspensions; emulsions; solutions; syrups; soft and hard gelatin capsules; transdermal patches; topical gels, creams and the like; vaginal suppositories; sterile injectable solutions; and sterile packaged powders, sublingual tablets, buccal tablets and buccal adhesive systems.
- the drug product is present in a solid pharmaceutical composition that may be suitable for oral administration.
- a solid composition of matter according to the present invention may be formed and may be mixed with and/or diluted by an excipient.
- the solid composition of matter may also be enclosed within a carrier which may be, for example, in the form of a capsule, sachet, tablet, paper, or other container.
- a carrier which may be, for example, in the form of a capsule, sachet, tablet, paper, or other container.
- the excipient serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, carrier, or medium for the composition of matter.
- excipients will be understood by those skilled in the art and may be found in the National Formulary, 19: 2404-2406 (2000), the disclosure of pages 2404 to 2406 being incorporated by reference herein in their entirety.
- suitable excipients include, but are not limited to, starches, gum arabic, calcium silicate, macrocrystalline cellulose, methacrylates, shellac, polyvinylpyrrolidone, cellulose, water, syrup, and methylcellulose.
- the drug product formulations can additionally include lubricating agents such as, for example, talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propyl hydroxybenzoates; sweetening agents; or flavoring agents.
- lubricating agents such as, for example, talc, magnesium stearate and mineral oil
- wetting agents such as, for example, talc, magnesium stearate and mineral oil
- emulsifying and suspending agents such as methyl- and propyl hydroxybenzoates
- sweetening agents or flavoring agents.
- Polyols, buffers, and inert fillers may also be used. Examples of polyols include, but are not limited to, mannitol, sorbitol, xylitol, sucrose, maltose, glucose, lactose, dextrose, and the like.
- Suitable buffers encompass, but are not limited to, phosphate,
- inert fillers which may be used encompass those which are known in the art and are useful in the manufacture of various dosage forms.
- the solid formulations may include other components such as bulking agents and/or granulating agents, and the like.
- the drug products of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
- the composition of matter of the present invention may be made by a direct compression process.
- the active drug ingredients may be mixed with a solid, pulverant carrier such as, for example, lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives or gelatin, and mixtures thereof, as well as with an antifriction agent such as, for example, magnesium stearate, calcium stearate, and polyethylene glycol waxes.
- a solid, pulverant carrier such as, for example, lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives or gelatin, and mixtures thereof, as well as with an antifriction agent such as, for example, magnesium stearate, calcium stearate, and polyethylene glycol waxes.
- the mixture may then be pressed into tablets using a machine with the appropriate punches and dies to obtain the desired tablet size.
- tablets for oral administration may be formed by a wet granulation process.
- Active drug ingredients may be mixed with excipients and/or diluents.
- the solid substances may be ground or sieved to a desired particle size.
- a binding agent may be added to the drug.
- the binding agent may be suspended and homogenized in a suitable solvent.
- the active ingredient and auxiliary agents may also be mixed with the binding agent solution.
- the resulting dry mixture is moistened with the solution uniformly. The moistening typically causes the particles to aggregate slightly, and the resulting mass is pressed through a stainless steel sieve having a desired size.
- the mixture is then dried in controlled drying units for the determined length of time necessary to achieve a desired particle size and consistency.
- the granules of the dried mixture are sieved to remove any powder.
- disintegrating, antifriction, and/or anti-adhesive agents are added.
- the mixture is pressed into tablets using a machine with the appropriate punches and dies to obtain the desired tablet size.
- the operating parameters of the machine may be selected by the skilled artisan.
- the above prepared core may be coated with a concentrated solution of sugar or cellulosic polymers, which may contain gum arabic, gelatin, talc, titanium dioxide, or with a lacquer dissolved in a volatile organic solvent or a mixture of solvents.
- sugar or cellulosic polymers which may contain gum arabic, gelatin, talc, titanium dioxide, or with a lacquer dissolved in a volatile organic solvent or a mixture of solvents.
- various dyes may be added in order to distinguish among tablets with different active compounds or with different amounts of the active compound present.
- the active ingredient may be present in a core surrounded by one or more layers including enteric coating layers.
- Soft gelatin capsules may be prepared in which capsules contain a mixture of the active ingredient and vegetable oil.
- Hard gelatin capsules may contain granules of the active ingredient in combination with a solid, pulverulent carrier, such as, for example, lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives, and/or gelatin.
- a solid, pulverulent carrier such as, for example, lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives, and/or gelatin.
- the formulation may be in the form of orally-administered tablets which contain the composition of matter of the present invention as set forth herein along with the following inactive ingredients: calcium phosphate tribasic, calcium sulfate, carnauba wax, cellulose, glyceryl monooleate, lactose, magnesium stearate, methylcellulose, pharmaceutical glaze, polyethylene glycol, stearic acid, sucrose, and titanium dioxide.
- Such ingredients may be present in amounts similar to those present in Premarin® (conjugated estrogens tablets, USP) made commercially available by Wyeth- Ayerst Laboratories of Philadelphia, Pennsylvania. Tablets employing the active ingredients of the invention may contain excipients similar to those contained in the 0.3 mg, 0.625 mg, and 1.25 mg tablets of Premarin® (conjugated estrogens tablets, USP).
- aqueous medium which contains an active ingredient or ingredients, a quantity of one or more surfactants sufficient to dissolve or suspend said active ingredients uniformly throughout the medium and other manufacturing additives as known to the art.
- the latter include granulating-binding agents such as gelatin; natural gums, such as acacia, tragacanth; starches, sodium alginate, sugars, polyvinylpyrrolidone; cellulose derivatives such as hydroxypropylmethylcellulose, polyvinyloxoazolidones; pharmaceutical fillers such as lactose, microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, calcium sulfate, dextrose, mannitol, sucrose; tabletting lubricants if needed such as calcium and magnesium stearate, stearic acid, talc, sterotex (alkaline stearate).
- the components may then be granulated, the resulting granules are dried, sieved and compressed into tablets or filled into capsules.
- Other oral product forms may be similarly prepared by art metliods such as chewable tablets, lozenges, troches, sustained or delayed release products or suspensions.
- the active ingredients comprise any medicament which has a low effective dose such as those below 20 mg per dosage unit. Most useful are those medicaments having a steroidal nucleus, the cyclopentanoperhydrophenanthrene ring system, in their chemical structures such as the estrogens or progestins.
- Examples of the former are ethinylestradiol, estrone, mestranol, 17-alpha- ethinyl estradiol-3-methylether esterified estrogens, and, especially estradiol, methyl testosterone.
- the dosage amounts and indications of these and other active ingredients are those described in the literature such as the Physician's Desk Reference.
- the progestins are megestrol actetate 3-ketodesogestrel, desogestrel, levo- desogestrel, norgestrel, gestodene, mestranol, norethindrone, norethindrone acetate.
- aqueous medium for the second ingredient of one of the embodiments of the invention is used within the custom of the pharmaceutical art. Primarily, it connotes a water medium, with added water-miscible solvents such as isopropanol or ethanol when needed, to support the active ingredient or pharmaceutical aids.
- a third potential ingredient of the present invention may include a surfactant acceptable in pharmaceutical manufacturing practice and selected from the three categories of surfactants: cationic, anionic and non-ionic compounds.
- the quantity of surfactant in the granulating mixture is enough to be non-toxic and to support the steroidal active ingredient in solution or suspension. Usually, this means very small, almost catalytic, quantities, such as less than 0.01% by weight. Applicant has devised a simple test procedure for determining the applicability of a selected surfactant for this process. Details are presented below.
- binding- granulating agents such as polyacrylamides, polyvinyloxoazolidones, sucrose, and sodium carboxymethylcellulose
- fillers such as lactose, talc, cellulosics, dibasic calcium phosphate, starches
- disintegrants if a tablet or capsule is formed such as croscarmellose sodium, starch, sodium carboxymethyl starch, veegum, ion exchange resins (amberlite), sodium bicarbonate
- lubricants for tablet compression such as polyethylene glycol 4000 and 5000, hydrogenated vegetable oils, light mineral oil.
- the practice of this invention depends on the novelty and practical benefits of using a low dose medicament, a pharmaceutically acceptable quantity of surfactant and an aqueous medium.
- Ingredients include, but are not limited to estradiol, sodium lauryl sulfate and water from a povidone solution.
- the therapeutic utility is demonstrated by oral administration of such a dosage unit from 1-5 times daily to a subject in need of treatment, for example for menopausal abnormalities.
- the dried granules may be filled into a capsule. Where extended or delayed release of the low dose medicament is desired the granules or capsule may be coated as known to the art.
- One procedure that may be followed to produce the tablets of the present invention may include the following. 1. Suspend the estradiol in a 1% povidone solution in which 0.005% sodium lauryl sulfate has been dispersed. 2. Blend the Cal-Star and lactose until homogeneous. 3. Granulate the blend from Step 2 with the suspension of estradiol in povidone solution from Step 1. 4. Dry the above granulation. 5. Screen and blend the dried granulation from Step 4 with the other ingredients. 6. Compress the blend from Step 5 into 164 mg tablets. Each tablet containing 2 mg of estradiol.
- Another protocol for Screening Surfactant for Low Dose Drug Suspensions follows. I. Prepare a 1% povidone stock solution in water. II. Prepare reference solution of 1% povidone—0.005% sodium lauryl sulfate (SLS). A. Prepare a 14.3% w/w solution with the SLS solution and estradiol. B. Prepare a 14.3% w/w solution with the SLS solution and spironolactone. C. Compare the estradiol solution and the spironolactone solution. If they have the same appearance, spironolactone can be used as the model drug and estradiol can be used for a check. III.
- SLS sodium lauryl sulfate
- A. Prepare 1% povidone-- 1% surfactant solutions. 1. Prepare 14.3% w/w solution with the surfactant and the steroidally derived drug. 2. Compare to reference solution. 3. If the surfactant/steroidal solution conforms to the reference solution: a. Dilute surfactant solution with 1% povidone solution in 0.5% increments; b. Determine the lowest concentration of surfactant that a flocculated suspension can be formed.
- Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g., solutions containing an active ingredient, sugar, and a mixture of ethanol, water, glycerol, and propylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, and saccharin. Thickening agents such as carboxymethylcellulose may also be used.
- such a formulation may comprise sterile aqueous injection solutions, non- aqueous injection solutions, or both comprising the composition of matter o f the present invention.
- aqueous injection solutions When aqueous injection solutions are prepared, the composition of matter may be present as a water soluble pharmaceutically acceptable salt.
- Parenteral preparations may contain anti-oxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient.
- Aqueous and non-aqueous sterile suspensions may include suspending agents and thickening agents.
- the formulations may be presented in unit- dose or multi-dose containers, for example sealed ampules and vials.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- the drug product is in the form of an injectable solution containing a predetermined amount ⁇ e.g., 25 mg) of the composition of matter in a sterile lyophilized cake which also contains lactose, sodium citrate, and simethicone.
- a suitable buffer e.g., sodium hydroxide or hydrochloric acid.
- Reconstitution may be carried out according to known methods, e.g., using a sterile diluent (5 mL) containing 2 percent by volume benzyl alcohol in sterile water.
- a preferred injectable solution is similar to Premarin® Intravenous made commercially available by Wyeth-Ayerst Laboratories.
- composition of matter also may be formulated such that it may be suitable for topical administration (e.g., vaginal cream).
- These formulations may contain various excipients known to those skilled in the art. Suitable excipients may include, but are not limited to, cetyl esters wax, cetyl alcohol, white wax, glyceryl monostearate, propylene glycol, monostearate, methyl stearate, benzyl alcohol, sodium lauryl sulfate, glycerin, mineral oil, water, carbomer, ethyl alcohol, acrylate adhesives, polyisobutylene adhesives, and silicone adhesives.
- the drug product may be in the form of a vaginal cream containing the composition of matter as set forth herein present in a nonliquefying base.
- the nonliquefying base may contain various inactive ingredients such as, for example, cetyl esters wax, cetyl alcohol, white wax, glyceryl monostearate, propylene glycol, monostearate, methyl stearate, benzyl alcohol, sodium lauryl sulfate, glycerin, and mineral oil.
- Such composition may be formulated similar to Premarin® Vaginal Cream made commercially available by Wyeth- Ayerst Laboratories.
- Dosage units for vaginal or rectal administration may be prepared in the form of suppositories which may contain the composition of matter in a mixture with a neutral fat base polyethylene glycol, or they may be prepared in the form of gelatin-rectal capsules which contain the active substance in a mixture with a vegetable oil or paraffin oil.
- an estrogenic compound comprising 0.05 to 3 mg of estrogens, preferably conjugated estrogens, and a progestational agent comprising 1.5 to 16 mg of a progestin may be administered to a subject.
- the estrogenic compound may be used to treat vasomotor symptoms including, but not limited to hot flashes, also known as hot flushes, cold flashes/flushes, night and day sweats, dry vagina, dry hair and skin, insomnia, bladder problems and moodiness.
- the estrogenic compound may also be used to treat menopause or may be used in conjunction with or as an estrogen replacement therapy or hormonal replacement therapy.
- the methods used in estrogen therapy in the present invention may include starting estrogen therapy at a high dose, and then lowering the dose once therapy has been shown to be effective.
- the estrogenic compound is administered in a therapeutic amount to a subject in a first dose is sufficient to alleviate vasomotor symptoms.
- the first dose may be administered daily, continuously and uninterruptedly for an effective time period until such time that therapy has been effectively established, preferably two to twelve weeks, more preferably four to eight weeks.
- the therapeutic amount of the estrogenic compound for the first dose is typically 0.05 to 3 mg of estrogens, more preferably 0.6 to 1.25 mg of estrogens.
- a second dose of a therapeutic amount of an estrogenic compound is administered to a subject.
- This second dose comprises a lower dosage of the therapeutic amount of the estrogenic compounds than the first dose.
- the therapeutic amount of the estrogenic compound in the second dose is 0.05 to 2.5 mg, and more preferably 0.25 to 0.5 mg per dose.
- the second dose is administered continuously and uninterruptedly until a time when all vasomotor symptoms and other symptoms relating to menopause have been alleviated and will not return.
- the methods, preparations and pharmaceutical products of the present invention may also provide for at least two or more dosage strengths of progestational agents over the course of the treatment period such that the dosages, when administered as provided herein, may result in an acceptable bleeding pattern.
- the initial dosing of the progestin may be relatively high to assist in inducing or establishing a nonproliferative endometrium. Typically, this effect may be evidenced by an absence of substantive mitotic activity.
- the dosing may be used to enhance the formation of nonproliferative endometrium and results in a reduction of random bleeding during the remainder of the treatment period.
- This dosage strength typically is administered for about 7 to about 120 days. This time period may be less than 7 days depending on the dosage.
- Administration of a high dosage may allow for a shorter initial period.
- the dosage amount of progestin is then either gradually reduced in a series of steps or is reduced in one step to a maintenance amount that is less than the initiation amount.
- the maintenance dose preferably is at least about 25% less than the initial dose and, most preferably, the maintenance amount is about half of the initiation dosage. More preferably the second dose is at least a 50% reduction than the initial dose of progestins.
- Subsequent doses may be greater than 50%, i.e., administering 20 mg in the first dose and dropping the dose all the way to 0.1 mg. At this point in the treatment period, the dosage amount is such that the nonproliferative or atrophic endometrium is maintained or continued.
- This dosage amount of progestin inhibits or decreases the potential for breakthrough bleeding and spotting, typical problems in traditional therapies.
- This dosage strength is typically administered for about two to four weeks for short-term therapies or may be administered indefinitely for longer therapies. The treatment period ends upon cessation of administration of the estrogen and progestin therapy.
- the amount of progestin is provided in an initiation step of the treatment period in an amount exhibiting progestin activity equivalent to less than 20 mg of megestrol acetate and is provided in a maintenance step during the treatment period in an amount exhibiting progestin activity equivalent to below about 10.0 mg of megestrol acetate.
- the amount of progestin activity is reduced by at least 25%; most preferably the amount of progestin is 50% of the amount in the maintenance step as the amount in the initiation step.
- the amount of progestin preferably is decreased in a series of steps to the maintenance step wherein the progestin activity is about half the amount administered in the initiation dosage.
- the progestin is provided in an initiation step of the treatment in an amount exhibiting progestin activity equivalent to an oral dose of about 1 mg to about 20 mg of megestrol acetate and is provided in a maintenance step during the treatment period in an amount exhibiting progestin activity equivalent to an oral dose of about 0.5 to about 10 mg of megestrol acetate; provided, however, that the amount of progestin activity is reduced in the maintenance step by at least 25%; most preferably the amount of progestin is 50% the amount in the maintenance step as the amount in the initiation step.
- a third step is most preferably reduced by an additional 50% from the second step.
- the amount of progestin when the amount of estrogen is about 0.625 mg may be either about 6 mg or about 12 mg in the initiation step, and about 3 mg or about 6 mg, respectively, in the remaining or maintenance step of the treatment period.
- the amount of progestin is preferably 5 mg or 10 mg, respectively, in the initiation step of the treatment period and approximately 2.5 mg or 5 mg in the remaining step or maintenance step of the treatment period.
- All amounts of progestin are in terms of biological equivalence to oral doses of megestrol acetate and all amounts of estrogen are in terms of biological equivalence to oral doses of conjugated estrogens.
- One skilled in the art will be able to compare the dose equivalency tables should they choose a progestin outside of megestrol acetate.
- the methods used in the present invention may include reducing the amount of a progestin given to a subject by starting out administering a high dose of a progestin agent to a subject and then gradually lowering the dose once therapy has been effectively established.
- a progestin agent may be lowered.
- the dosage of the progestin agent may be lowered.
- One skilled in the art will be able to choose additional regimens based upon this information.
- the first dose may be administered daily, continuously and uninterruptedly for an effective time period until such time that therapy has been effectively established, preferably one week to two months, more preferably two to six weeks.
- the initiation dosage amount of progestin may be sufficient to enhance formation of or may help establish a nonproliferative or atrophic endometrium.
- the treatment may further substantially induce bleeding and then obviate or reduce random bleeding.
- the maintenance dosage amount is sufficient and effective for continuing or maintaining the nonproliferative endometrium established by the initiation dosage of progestin.
- the maintenance dosage amount further inhibits and decreases breakthrough bleeding and spotting observed in traditional therapies.
- the methods may be used for a number of treatments such as, but not limited to, vasomotor symptoms; atrophic vaginitis; osteoporosis; hypoestrogenism due to hypogonadism, castration, or other primary ovarian failure, among others.
- the administration of estrogen and progestin according to the present invention may be continuous for a short- term, for example, to treat vasomotor symptoms, or may be continuous for a long-term, for example for osteoporosis.
- One example of long-term use would be from the onset of menopause until death.
- the pharmaceutical product of the invention may be provided in a variety of forms, such that the sequential dosage units may be easily accessible by a subject.
- the pharmaceutical product may be provided as a pharmaceutical package containing the sequential dosages in an arrangement suitable for daily administration of the appropriate dosages of estrogen and progestin.
- the number of dosages in each package may depend on the therapy and whether it is a long-term therapy for hormone deficiencies, or a short-term therapy.
- the pharmaceutical product may include a kit or package with daily dosages arranged for proper sequential administration. The sequence or arrangement of the dosage units will correspond to the stages of daily administration.
- the present invention is primarily concerned with the treatment of human subjects, but the invention also may be carried out on animal subjects, particularly mammalian subjects such as mice, rats, dogs, cats, livestock and horses for veterinary purposes, and for drug screening and drug development purposes.
- the internal standard stock solution was prepared in a 100 mL volumetric flask by weighing 9.97 mg internal standard and dissolving it in 100 mL methanol to obtain a concentration of 100 ng/ ⁇ L of the internal standard. This solution was labelled "IS stock solution 100 ng/ ⁇ L in methanol”.
- the IS working solution was prepared by diluting the IS stock solution with methanol to obtain the concentration of 0.200 ng/ ⁇ L.
- the internal standard stock solution 5°C ⁇ 3°C and the working solution were stored in a refrigerator at 5°C ⁇ 3°C.
- Calibration standards were prepared freshly for each run by spiking 25 1.1L of the corresponding working solution to 1 mL of plasma.
- the working solutions were prepared from the stock solution SSI as described below.
- Table 1 below illustrates the preparation of the working solutions and calibration standards.
- the quality control samples were prepared in the same way as the calibration standards.
- the working solutions were prepared from stock solution SS2.
- the QC samples were prepared at the beginning of measurement. After preparation, the QC samples were stored at the same conditions as tire study samples.
- Table 2 shows the preparation of the QC samples.
- the solvents and reagents were of the same type and quality as used during method validation. All solvents and reagents including water were of p.a. quality or better.
- the reagents used are included toluene, diisopropylether, methanol and sodium hydroxide.
- the time measured represents the number of hours passed post dosing.
- Subjects 2, 4, 6, 8 and 10 all received a 6 mg dose of megestrol acetate.
- Subjects 1, 3, 5, 7 and 9 all received a 1.5 mg dose of megestrol acetate.
- a third measurement was not possible due to insufficient sample.
- 3 series of plasma calibration curves were measured (prevalidation run not considered). The statistics on regression parameters and backcalculated calibration standards are presented in the following tables.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006510080A JP2006522833A (en) | 2003-04-11 | 2004-04-08 | Administration of estrogen and progestin |
MXPA05010871A MXPA05010871A (en) | 2003-04-11 | 2004-04-08 | Methods of administering estrogens and progestins. |
AU2004229565A AU2004229565B2 (en) | 2003-04-11 | 2004-04-08 | Methods of administering estrogens and progestins |
EP04750182A EP1622623A4 (en) | 2003-04-11 | 2004-04-08 | Methods of administering estrogens and progestins |
CA002521471A CA2521471A1 (en) | 2003-04-11 | 2004-04-08 | Methods of administering estrogens and progestins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46228503P | 2003-04-11 | 2003-04-11 | |
US60/462,285 | 2003-04-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004091535A2 true WO2004091535A2 (en) | 2004-10-28 |
WO2004091535A3 WO2004091535A3 (en) | 2005-03-24 |
Family
ID=33299932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/011662 WO2004091535A2 (en) | 2003-04-11 | 2004-04-08 | Methods of administering estrogens and progestins |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040259851A1 (en) |
EP (1) | EP1622623A4 (en) |
JP (1) | JP2006522833A (en) |
CA (1) | CA2521471A1 (en) |
MX (1) | MXPA05010871A (en) |
WO (1) | WO2004091535A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007144151A1 (en) * | 2006-06-13 | 2007-12-21 | Bayer Schering Pharma Aktiengesellschaft | Step-down estrogen regimen for women receiving estrogen therapy |
US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
CA2569738A1 (en) * | 2004-06-07 | 2005-12-22 | Duramed Pharmaceuticals, Inc. | Dispenser for progestin used for acute and maintenance treatment of dub |
US20060040904A1 (en) * | 2004-08-17 | 2006-02-23 | Ahmed Salah U | Vaginal cream compositions, kits thereof and methods of using thereof |
ATE543489T1 (en) * | 2005-05-26 | 2012-02-15 | Teva Womens Health Inc | ORAL DOSAGE FORMS CONTAINING PROGESTERONE AND METHODS OF USE AND MANUFACTURING THEREOF |
EP2289487A1 (en) * | 2005-12-27 | 2011-03-02 | Teva Women's Health, Inc. | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
US8867122B2 (en) | 2006-12-19 | 2014-10-21 | Selex Es Ltd | Optical parametric oscillator |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3230142A (en) * | 1963-03-25 | 1966-01-18 | Upjohn Co | Oral contraceptive compositions and methods |
NL6615481A (en) * | 1966-11-02 | 1968-05-03 | ||
US3487152A (en) * | 1967-02-07 | 1969-12-30 | Hoffmann La Roche | Tablets containing 7 - chloro - 2 - methylamino - 5 - phenyl - 3h - 1,4 - benzodiazepine-4-oxide and conjugated estrogenic substances |
US3568828A (en) * | 1967-03-01 | 1971-03-09 | Squibb & Sons Inc | Modified sequential oral contraceptive |
US3591688A (en) * | 1969-08-22 | 1971-07-06 | American Home Prod | Method of preventing ovulation and composition therefor |
US3639600A (en) * | 1969-08-28 | 1972-02-01 | Upjohn Co | Process of establishing cyclicity in a human female |
US3795734A (en) * | 1970-04-20 | 1974-03-05 | American Home Prod | Cyclic regimen of hormone administration for contraception |
US3733407A (en) * | 1971-08-25 | 1973-05-15 | Syntex Corp | Menopause treatment |
US3836651A (en) * | 1972-02-22 | 1974-09-17 | Biolog Concepts Inc | Novel oral contraceptive combination |
DE2310963A1 (en) * | 1972-04-14 | 1974-09-05 | Schering Ag | METHOD OF CONTRACTION BY FOLLOWING STAGE COMBINATION PREPARATIONS |
US3969502A (en) * | 1972-04-14 | 1976-07-13 | Schering Aktiengesellschaft | Method for contraception by the administration of sequential contraceptive preparations |
US3932635A (en) * | 1972-04-24 | 1976-01-13 | Syntex Corporation | Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens |
US3942641A (en) * | 1972-05-05 | 1976-03-09 | Syntex Corporation | Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens |
GB1399162A (en) * | 1972-06-29 | 1975-06-25 | Schering Ag | 6-keto-delta1,3,5-10-steroids and process for the manufacture of 6-keto-delta1,3,5-10-steroids |
US4066757A (en) * | 1973-03-26 | 1978-01-03 | Ortho Pharmaceutical Corporation | Oral contraceptive regimen |
DE2365103C3 (en) * | 1973-12-21 | 1980-08-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Use of hormones for contraception |
US4147783A (en) * | 1974-02-28 | 1979-04-03 | Akzona Incorporated | Oral pharmaceutical preparation |
NL7506407A (en) * | 1975-05-30 | 1976-12-02 | Akzo Nv | PROCESS FOR PREPARING AN ORAL ACTIVE PHARMACEUTICAL PREPARATION. |
US4027019A (en) * | 1975-07-24 | 1977-05-31 | Ortho Pharmaceutical Corporation | 3-Oximes of D-17α-ethynyl-19-nortestosterone esters and method |
US4154820A (en) * | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
US4145416A (en) * | 1976-06-23 | 1979-03-20 | Schering, A.G. | Novel agents and novel methods for treatment of climacteric disturbances |
US4291028A (en) * | 1977-12-30 | 1981-09-22 | Nichols Vorys | Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system |
US4292315A (en) * | 1977-12-30 | 1981-09-29 | Nichols Vorys | Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system |
US4210644A (en) * | 1978-02-23 | 1980-07-01 | The Johns Hopkins University | Male contraception |
DE2818164A1 (en) * | 1978-04-21 | 1979-10-31 | Schering Ag | 1,3-DIBENZOIC ACID ESTER OF 17ALPHA-ETHINYL-7 ALPHA -METHYL-1,3,5 (10) -OESTRATRIEN- 1,3,17 BETA -TRIOLS, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREOF |
US4756907A (en) * | 1978-10-17 | 1988-07-12 | Stolle Research & Development Corp. | Active/passive immunization of the internal female reproductive organs |
NL8001593A (en) * | 1980-03-18 | 1981-10-16 | Akzo Nv | MULTI-PHASIC COMBINATION PREPARATION FOR ORAL ANTI-CONCEPTION. |
US4315925A (en) * | 1980-05-30 | 1982-02-16 | University Of Kentucky Research Foundation | Method of administering natural female sex hormones |
US4383993A (en) * | 1980-05-30 | 1983-05-17 | University Of Kentucky Research Foundation | Nasal dosage forms containing natural female sex hormones |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4315033A (en) * | 1981-01-22 | 1982-02-09 | Lawrason F Douglas | Method of treating menopausal symptoms |
US4425339A (en) * | 1981-04-09 | 1984-01-10 | Syntex (U.S.A.) Inc. | Treatment of menopausal symptoms |
US4390531A (en) * | 1981-08-10 | 1983-06-28 | Syntex Pharmaceuticals International Ltd. | Method of contraception using peak progestogen dosage |
US4381298A (en) * | 1981-10-13 | 1983-04-26 | Coulson Patricia B | Oral male contraceptive composition |
US4921843A (en) * | 1988-10-20 | 1990-05-01 | Pasquale Samuel A | Contraception system and method |
US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4512986A (en) * | 1983-07-26 | 1985-04-23 | Research Triangle Institute | Progrestationally active steroids |
US4826831A (en) * | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
US4628051A (en) * | 1983-09-26 | 1986-12-09 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
US4544554A (en) * | 1983-09-26 | 1985-10-01 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
US4616006A (en) * | 1983-09-26 | 1986-10-07 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
US4530839A (en) * | 1983-09-26 | 1985-07-23 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
DE3347125A1 (en) * | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | MULTI-STAGE COMBINATION PREPARATION AND ITS USE FOR ORAL CONTRACTION |
US5010070A (en) * | 1987-06-15 | 1991-04-23 | Warner-Lambert Company | Graduated estrogen contraceptive |
US4962098A (en) * | 1987-06-15 | 1990-10-09 | Warner-Lambert Company | Graduated estrogen contraceptive |
DE3505433A1 (en) * | 1985-02-16 | 1986-08-21 | Basf Ag, 6700 Ludwigshafen | DIRECT TABLETING AIDS |
DE3510555A1 (en) * | 1985-03-21 | 1986-09-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | ESTRIOLESTER |
US4816257A (en) * | 1985-09-20 | 1989-03-28 | Research & Education Institute, Harbor-Ucla Medical Center Inc. | Method for producing an in vivo environment suitable for human embryo transfer |
US4764378A (en) * | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
US5208225A (en) * | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
US4762717A (en) * | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
US4816258A (en) * | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
US4855305A (en) * | 1987-03-23 | 1989-08-08 | Applied Medical Research | Compositions and methods of effecting contraception utilizing melatonin |
ATE66149T1 (en) * | 1987-07-06 | 1991-08-15 | Akzo Nv | PHARMACEUTICAL DOSING UNIT FOR PREVENTION TREATMENT OF CLIMATE DISORDERS. |
US4900734A (en) * | 1987-08-27 | 1990-02-13 | Maxson Wayne S | Novel pharmaceutical composition containing estradiol and progesterone for oral administration |
US5276022A (en) * | 1987-09-24 | 1994-01-04 | Jencap Research Ltd. | Hormone preparation and method |
US5108995A (en) * | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
GB8726304D0 (en) * | 1987-11-10 | 1987-12-16 | Secr Defence | Particle asymmetry analyser |
DE3741801A1 (en) * | 1987-12-07 | 1989-06-15 | Schering Ag | 17-Methylene-estratrienes |
GB8813353D0 (en) * | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
NL8801670A (en) * | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | PHARMACEUTICAL PREPARATION. |
US5043331A (en) * | 1989-06-15 | 1991-08-27 | Orion-Yhtyma Oy | Treatment of postmenopausal disorders |
US5130137A (en) * | 1989-08-09 | 1992-07-14 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders |
US5200197A (en) * | 1989-11-16 | 1993-04-06 | Alza Corporation | Contraceptive pill |
IE71203B1 (en) * | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
IE62665B1 (en) * | 1990-12-17 | 1995-02-22 | Akzo Nv | Contraceptive regimen |
DE4104385C1 (en) * | 1991-02-09 | 1992-08-13 | Marika Dr.Med. 6509 Framersheim De Ehrlich | |
ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
HU222501B1 (en) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | Controlled release pharmaceutical composition containing mpa or mga and process for its preparation |
US5300687A (en) * | 1991-07-18 | 1994-04-05 | Ortho Pharmaceutical Corporation | Trifluoromethylbenzylphosphonates useful in treating osteoporosis |
US5464871A (en) * | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
US5210081A (en) * | 1992-02-26 | 1993-05-11 | American Home Products Corporation | Alkali metal 8,9-dehydroestrone sulfate esters |
IL107343A (en) * | 1992-11-02 | 2003-10-31 | Wyeth Corp | PHARMACEUTICAL COMPOSITION FOR LOWERING BLOOD LIPID LEVEL, COMPRISING, 17alpha-DIHYDROEQUILENIN |
DE69433994T2 (en) * | 1993-01-19 | 2005-09-22 | Endorecherche Inc., Ste-Foy | THERAPEUTIC USES AND ADMINISTRATION SYSTEMS OF DEHYDROEPIANDROSTERONE |
US5498755A (en) * | 1994-08-23 | 1996-03-12 | Chandraratna; Roshantha A. | Disubstituted aryl and heteroaryl imines having retinoid-like biological activity |
US5759577A (en) * | 1995-01-17 | 1998-06-02 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US5547948A (en) * | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US5861431A (en) * | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
US5998639A (en) * | 1995-11-06 | 1999-12-07 | Akzo Nobel, N.V. | Sulfatation of estrogen mixtures |
US5654011A (en) * | 1996-07-30 | 1997-08-05 | Energetics, Inc. | Dietary supplements |
US6040333A (en) * | 1996-07-30 | 2000-03-21 | Energetics, Inc. | Dietary supplements |
US5807586A (en) * | 1996-07-30 | 1998-09-15 | Energetics, Inc. | Method of dietary supplementation |
EP1052980A1 (en) * | 1998-10-09 | 2000-11-22 | PHARMACIA & UPJOHN COMPANY | Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis |
US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
US20010034340A1 (en) * | 2000-03-20 | 2001-10-25 | American Home Products Corporation | Hormone replacement therapy |
HUP0500346A2 (en) * | 2001-03-16 | 2005-07-28 | Wyeth | Use of conjugated estrogens for producing pharmaceutical compositions effective in estrogen replacement therapy |
US20030004145A1 (en) * | 2001-05-16 | 2003-01-02 | Leonard Thomas W. | Treatment of conditions relating to hormone deficiencies by administration of progestins |
US6510799B2 (en) * | 2001-07-02 | 2003-01-28 | Magna Force, Inc. | Apparatus, systems and methods for levitating and moving objects |
-
2004
- 2004-04-08 WO PCT/US2004/011662 patent/WO2004091535A2/en active Search and Examination
- 2004-04-08 JP JP2006510080A patent/JP2006522833A/en not_active Withdrawn
- 2004-04-08 CA CA002521471A patent/CA2521471A1/en not_active Abandoned
- 2004-04-08 US US10/821,278 patent/US20040259851A1/en not_active Abandoned
- 2004-04-08 MX MXPA05010871A patent/MXPA05010871A/en active IP Right Grant
- 2004-04-08 EP EP04750182A patent/EP1622623A4/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of EP1622623A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007144151A1 (en) * | 2006-06-13 | 2007-12-21 | Bayer Schering Pharma Aktiengesellschaft | Step-down estrogen regimen for women receiving estrogen therapy |
WO2007144152A2 (en) * | 2006-06-13 | 2007-12-21 | Bayer Schering Pharma Aktiengesellschaft | Extended step-down estrogen regimen |
WO2007144152A3 (en) * | 2006-06-13 | 2008-06-12 | Bayer Schering Pharma Ag | Extended step-down estrogen regimen |
US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
US11617751B2 (en) | 2006-07-06 | 2023-04-04 | Bayer Pharma AG | Pharmaceutical composition containing a tetrahydrofolic acid |
Also Published As
Publication number | Publication date |
---|---|
EP1622623A4 (en) | 2009-03-18 |
CA2521471A1 (en) | 2004-10-28 |
MXPA05010871A (en) | 2005-11-25 |
US20040259851A1 (en) | 2004-12-23 |
WO2004091535A3 (en) | 2005-03-24 |
AU2004229565A1 (en) | 2004-10-28 |
EP1622623A2 (en) | 2006-02-08 |
JP2006522833A (en) | 2006-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7683047B2 (en) | Treatment of conditions relating to hormone deficiencies by administration of progestins | |
AU2002309919A1 (en) | Treatment of conditions relating to hormone deficiencies by administration of progestins | |
EP1359920B1 (en) | Uses of oral formulations for the treatment of female sexual dysfunction | |
US20060154907A1 (en) | Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy | |
AU2002232759A1 (en) | Methods and formulations for the treatment of female sexual dysfunction | |
AU2003210757B2 (en) | Method of hormonal therapy | |
AU2002243411A1 (en) | Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy | |
US20040259851A1 (en) | Methods of administering estrogens and progestins | |
US20030216366A1 (en) | Step-down estrogen therapy | |
AU2004229565B2 (en) | Methods of administering estrogens and progestins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004229565 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2521471 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/010871 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006510080 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2004229565 Country of ref document: AU Date of ref document: 20040408 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004229565 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004750182 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004750182 Country of ref document: EP |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) |